China's Fosun Pharma-backed Gland Pharma on Friday said its Board has approved the appointment of Shyamakant Giri, as the new chief executive officer of the company.
Giri is expected to join the Gland with effect from January 15, 2025, Gland said in a statement to stock exchanges.
Srinivas Sadu, who is the incumbent CEO and executive chairman, will continue to be the executive chairman of the company and support the company’s next phase of growth.
Giri is currently the president, India business and emerging markets of US-based Amneal Pharmaceuticals, responsible for the commercial expansion and growth in India and Rest of the World markets.
Previously, Giri was associated with Rivaara Labs as the CEO. Earlier, Giri was associated in various roles with Abbott India, AbbVie (India Region) and Abbott Diagnostics for almost eighteen years (2002-2020).
"Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in leading Indian and multinational organizations across Asia, Africa, MENA & LATAM markets," Gland said in a statement.
"He possesses rich experience in creating new ventures and improving existing businesses, developing leaders, identifying opportunities for value creation, and executing with discipline," the statement added.
Giri started his professional career with Wockhardt and was associated during the period 1999-2002. He has done his master’s in marketing management from Jamnalal Bajaj Institute of Management Studies and also holds a master’s degree in science (organic chemistry) from Mumbai University.
He completed his executive programme from INSEAD, Singapore and executive programme in hospital management from Indian Institute of Management, Ahmedabad.
Giri is expected to join the Gland with effect from January 15, 2025, Gland said in a statement to stock exchanges.
Srinivas Sadu, who is the incumbent CEO and executive chairman, will continue to be the executive chairman of the company and support the company’s next phase of growth.
Giri is currently the president, India business and emerging markets of US-based Amneal Pharmaceuticals, responsible for the commercial expansion and growth in India and Rest of the World markets.
Previously, Giri was associated with Rivaara Labs as the CEO. Earlier, Giri was associated in various roles with Abbott India, AbbVie (India Region) and Abbott Diagnostics for almost eighteen years (2002-2020).
"Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in leading Indian and multinational organizations across Asia, Africa, MENA & LATAM markets," Gland said in a statement.
"He possesses rich experience in creating new ventures and improving existing businesses, developing leaders, identifying opportunities for value creation, and executing with discipline," the statement added.
Giri started his professional career with Wockhardt and was associated during the period 1999-2002. He has done his master’s in marketing management from Jamnalal Bajaj Institute of Management Studies and also holds a master’s degree in science (organic chemistry) from Mumbai University.
He completed his executive programme from INSEAD, Singapore and executive programme in hospital management from Indian Institute of Management, Ahmedabad.
You may also like
Alex Pereira shuts down Jake Paul fight call-out with perfect response
Congress Demands Resignation of Union Minister Pralhad Joshi Amid Family FIR Controversy
The common car modification that leads to £2,500 fines and revoked insurance
Jailed MP Amritpal Singh, two Canada-based handlers blamed for murder in Punjab (2nd Lead)
MP: Nitin Gadkari to address seminar on new technology on road construction tomorrow
